BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy · Delayed Price · Currency is EUR | Market Cap | 10.24B +5.0% |
| Revenue (ttm) | 2.81B +9.9% |
| Net Income | 233.08M -48.7% |
| EPS | 1.21 -48.4% |
| Shares Out | n/a |
| PE Ratio | 43.94 |
| Forward PE | 10.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21 |
| Open | 50.50 |
| Previous Close | 51.88 |
| Day's Range | 50.50 - 51.88 |
| 52-Week Range | 42.78 - 55.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense experti...
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented fo...
BioMarin Pharmaceutical Transcript: AGM 2026
The meeting established a quorum and proceeded with four proposals, including director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed by majority vote, with final results to be published in a Form 8-K.
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shar...
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we...
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration...
BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026
Amicus acquisition completed, boosting 2026 revenue growth outlook to 20% and expanding the commercial portfolio with Galafold and Pombiliti/Opfolda. Q1 revenues rose to $766M, driven by enzyme therapies and Voxzogo, with strong patient demand and new launches supporting future growth.
BioMarin Pharmaceutical Slides: Q1 2026
BioMarin Pharmaceutical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
BioMarin Pharmaceutical Earnings release: Q1 2026
BioMarin Pharmaceutical released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Quarterly report: Q1 2026
BioMarin Pharmaceutical has published its Q1 2026 quarterly earnings report on May 4, 2026.
BioMarin Reports First Quarter 2026 Financial and Operating Results
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt...
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with ...
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to ...
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf...
BioMarin Announces Board Leadership Transition
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.
BioMarin Pharmaceutical Proxy statement: Proxy filing
BioMarin Pharmaceutical filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioMarin Pharmaceutical Proxy statement: Proxy filing
BioMarin Pharmaceutical filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, se...
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, buildin...
BioMarin Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 13% in 2025, with strong performance from Voxzogo and enzyme therapies. Key 2026 catalysts include major phase III readouts, the Amicus acquisition, and new product launches. Commercial focus remains on expanding access, managing competition, and leveraging operational synergies.
BioMarin Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Revenue grew 13% in 2025, with high single-digit growth expected in 2026. Key pipeline milestones include phase III data for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency. The Amicus acquisition is set to expand the portfolio and drive accretion by 2027.
BioMarin Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
A strategic refresh has driven recent acquisitions and a focus on pipeline expansion, with 2026 guidance reflecting competitive and revenue headwinds but projecting solid growth in enzyme therapies and skeletal conditions. Key products like Voxzogo and Palynziq are positioned for continued growth, while new clinical milestones and the Amicus acquisition are expected to drive long-term value.
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy app...